Dialysis industry news

Stories from the dialysis comunity across the globe.

DaVita healthCare Partners Inc. Analyst Rating Update - News Watch International PDF Print

DaVita healthCare Partners Inc. (NYSE:DVA) has received a hold rating for the short term, according to the latest rank of 3 from research firm, Zacks. The company received an average rating of 1.8 from 10 analysts. 6 have rated it as a strong buy. 4 analysts have rated the company at hold.

Many analysts have commented on the company rating. Baird upgrades its view on DaVita healthCare Partners Inc. (NYSE:DVA) according to the research report released by the firm to its investors. The shares have now been rated Outperform by the stock experts at the ratings house. Earlier, the shares had a rating of Neutral. Baird raises the price target from $75 per share to $95 per share on DaVita healthCare Partners Inc.. The rating by the firm was issued on April 27, 2015. DaVita healthCare Partners Inc. (NYSE:DVA) shares are expected to touch $89.67 in the short term. This short term price target has been shared by 6 analysts. However, the standard deviation of short term price estimate has been valued at 5.75. The target price could hit $96 on the higher end and $83 on the lower end. Mondays trading session turned out to be a no-profit no-loss event for DaVita healthCare Partners Inc. (NYSE:DVA). The opening trade occurred at $79.95 and the highest and the lowest points of the day were $80.3 and $79.6101 respectively. The final trade was registered at $80.28 and the volume by the end of the day had touched 874,348 shares. The 52-week high of the stock is $85.17 and the 52-week low is $71.43. According to the current valuation, the market cap of the company is $17,300 million and the total number of shares available in public circulation is 215,500,000. DaVita HealthCare Partners Inc. has dropped 0.95% in the last five trading days, however, the shares have posted positive gains of 0.39% in the last 4 weeks. DaVita HealthCare Partners Inc. has dropped 2.93% during the last 3-month period . Year-to-Date the stock performance stands at 5.99%. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged that Jiganti Jeanine Marie, officer (Chief Compliance Officer) of Davita Healthcare Partners Inc., had unloaded 1,311 shares at an average price of $81.37 in a transaction dated on August 10, 2015. The total value of the transaction was worth $106,676. DaVita HealthCare Partners Inc., formerly DaVita Inc., is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2011, the Company provided dialysis and administrative services through a network of 1,809 outpatient dialysis centers located in the United States throughout 43 states and the District of Columbia, serving a total of approximately 142,000 patients. It also provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services throughout the United States. In July 2013, DaVita, a division of DaVita HealthCare Partners Inc announced the acquisition of the dialysis operations of Malaysias Caring Dialysis Centre Group (CDC Group) by DVA (Malaysia) Sdn Bhd. NO COMMENTS LEAVE A REPLY Cancel reply


Smoking Increases Risk of Some Renal Cell Cancer Subtypes - Renal and Urology News PDF Print
August 18, 2015 Smoking Increases Risk of Some Renal Cell Cancer Subtypes - Renal and Urology News
Higher risk for clear cell, papillary renal cell carcinoma, but not chromophobe histology.

(HealthDay News) -- Smoking is a risk factor for clear cell and papillary renal cell carcinoma, but not for the chromophobe subtype, according to a study published in The Journal of Urology.

Neel H. Patel, M.D., from the State University of New York in Buffalo, and colleagues examined the correlation between smoking and renal cell carcinoma subtype. Data were collected from 816 patients with nonfamilial renal cell carcinoma (705) or benign pathology (111) undergoing nephrectomy.

The researchers found that 51% of patients reported smoking, including 21% active smokers and 30% former smokers. Compared with benign histology, active smoking was more common with clear cell or papillary cell carcinoma (23 and 26%, respectively, versus 14%; P < 0.05each). Active smoking was less common with chromophobe renal cell carcinoma (6%; P < 0.05 versus clear cell or papillary). Any smoking history was also less common with chromophobe versus clear cell or papillary histology (26% versus 53% [P = 0.003] or 58% [P = 0.001]). For clear cell and papillary histologies, but not chromophobe histology, independent associations with active smoking persisted after multivariable adjustment (odds ratios, 2.2 and 2.4, respectively; both P < 0.05).

"These findings underscore distinct carcinogenic mechanisms underlying the various renal cell carcinoma subtypes," the authors write.


  1. Patel, NH; Attwood, KM; Hanzly, M; The Journal of Urology; doi: 10.1016/j.juro.2015.03.125.


A healthy diet can keep dialysis away - Honolulu Star-Advertiser PDF Print

It’s alarming indeed that Hawaii is seeing a boom in dialysis centers due to more chronic kidney disease — with no change in trend in sight. Unless, of course, folks start heeding the very simple yet very effective message to adopt a healthier, less sugary diet and a more active lifestyle.

“It really is a public health crisis,” said Dr. James Ireland, a kidney specialist. “Every year we’re seeing more and more patients. The line is still going up. We’re not even plateauing.” Login for more...

Forgot Password

Current print subscribers, activate your premium content account for unlimited online access & commenting Find subscription offers in your area and choose the package that suits your reading preferences.

14 day premium online access and commenting ability on StarAdvertiser.com


Syria: Support for dialysis saves lives - ICRC (press release) PDF Print

Every month, the dialysis centre in Homs receives nearly 100 patients with kidney problems. Amidst ongoing conflict in Syria, the daily health problems of thousands of Syrians have dropped off the radar. But with ICRC support, the Syrian Arab Red Crescent is keeping these services running.

 Since the beginning of the year, the ICRC has supported some 3,000 dialysis sessions across the country, on both sides of the front line.

Are you living in Syria? Do you need dialysis? Please contact the Syrian Arab Red Crescent's clinics for more information.


Rockwell Medical, Inc. Analyst Rating Update - American Trade Journal PDF Print

Rockwell Medical, Inc. (NASDAQ:RMTI) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 2.55 by 6 Wall Street Analysts. 3 analysts have added the shares in their list of strong buys. 1 analysts have advised hold. 2 has rated the company as strong sell.

Many analysts have commented on the company rating. Equity Analysts at the Brokerage Firm, Bank of America, reinstates their rating on the shares of Rockwell Medical, Inc. (NASDAQ:RMTI). Bank of America has a Neutral rating on the shares. The rating by the firm was issued on July 8, 2015. Rockwell Medical, Inc. (NASDAQ:RMTI) stock has received a short term price target of $ 15 from 6 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $8.15. The higher estimate of target price is $26 , while the lower price target estimate is $4 Rockwell Medical, Inc. (NASDAQ:RMTI) witnessed a decline in the market cap on Monday as its shares dropped 0.08% or 0.01 points. After the session commenced at $12.52, the stock reached the higher end at $12.65 while it hit a low of $12.05. With the volume soaring to 736,811 shares, the last trade was called at $12.64. The company has a 52-week high of $18.8999. The company has a market cap of $635 million and there are 50,223,000 shares in outstanding. The 52-week low of the share price is $8.095. Rockwell Medical, Inc. has lost 10.29% in the last five trading days and dropped 29.82% in the last 4 weeks. Rockwell Medical, Inc. is up 20.96% in the last 3-month period. Year-to-Date the stock performance stands at 22.96%. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Rockwell Medical, Inc., Chioini Robert L, had purchased 4,910 shares in a transaction dated on August 14, 2015. The transaction was executed at $11.96 per share with total amount equaling $58,724. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.


<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 12 of 4210
Share |
Copyright © 2018 Global Dialysis. All Rights Reserved.